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Primary Papillary Serous Carcinoma of the Peritoneum: A Case
of Complete Remission of Bulky Peritoneal Disease After
Chemotherapy

Walid A. Saleh, MD,* Cosmas J. M. Van de Ven, MD,* and Wooshin Kim, MD'

Peritoneal papillary serous carcinoma is a rare tumor that involves ihe surface ofthe pelvic andior
abdominal peritoneum. Long-ierm survival among patients with this tumor has been rare. Most
patients with this cancer have been treated with debulking surgeiy and postoperative chemotherapy.
A case of incompletely resected peritoneal papillary serous carcinoma with a complete response to
cisplatin-based chemotherapy is reported. Subsequent laparotomy revealed no residual tumor. This
case suggests that primary chemotherapy may be successful in treating unresectable primary
papillary serous tumors ofthe peritoneum. (Henry Ford Hosp MedJ 1992;40:136-8)

P

apillary serous carcinoma (PSC) of the peritoneum was first
described by Swerdlow (1) in 1959. It involves diffusely the
peritoneum, histologically resembles PSC of the ovary, but either spares the surface of the ovary or involves it only microscopically (2). About 130 cases have been described under a variety of names including mesotheliomas, mesodermoma, peritoneal PSC, papillary carcinoma from extraovarian tissue, serous
surface papillary carcinoma of the ovary, and peritoneal carcinomatosis of unknown primary site. There is still no consensus regarding nomenclature, histogenesis, immunohistochemical characteristics, clinical behavior, and treatment.

Case Report
A 75-year-old white female, gravida 3, para 3, underwent surgery in
a local hospital for possible incarcerated inguinal hernia. There was a
four-month history of gradually increasing abdominal girth, and on admission her abdomen was markedly distended. She denied any change
in weight. Physical examination confirmed the presence of abdominal
distension and tympany and hyperactive bowel sounds and disclosed a
3 cm ovoid nontender, nonreducible mass in the right inguinal area. On
admission, x-rays and laboratory tests were reportedly normal. With
the patient under spinal anesthesia, a right incarcerated femoral hernia
sac was opened. During exploration, muhiple polypoid implants suggestive of carcinomatosis along with a large amount of brown-colored
peritoneal fluid and necrotic tumor material were encountered. There
was no evidence of bowel in the hernia. The incision was extended and
abdominal exploration revealed marked ascites, diffuse tumor infiltration of the entire pelvis and small bowel, and "caking" of the lower
third of the omentum. The liver and upper abdominal structures were
not involved, and there was no evidence of bowel obstruction. After
multiple biopsies were taken from the omentum, hernial sac, and pelvic
peritoneum (Figure), the incision was closed as the tumor was considered to be unresectable. The postoperative course was uneventful except for mild ileus. On the recommendation of the medical oncologist,
the patient received nine courses of Cytoxan and carboplatin over a total
of eight months following the usual protocol for ovarian carcinoma.
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Follow-up visits revealed that the patient was doing well with no clinical evidence of disease. The carcinoembryonic antigen (CEA) and CA
125 levels were consistently normal. After completion of the chemotherapy, abdominal computed tomography (CT) revealed a 1 cm soft
tissue density at the level of the cecum, which was unchanged from a
previous CT one month earlier.
The patient was referred to Henry Ford Hospital for a second exploratory laparotomy 11 months after the original surgery. She underwent
lysis of adhesions, cytology washings, total abdominal hysterectomy
and bilateral salpingo-oophorectomy, selective pelvic and paraaortic
lymph node dissection, omentectomy, and repair of right inguinal hernia. There were dense adhesions around the bowel and adnexae. Both
ovaries were atrophic, about 1 cm in greatest diameter. A 2 cm nodule
was found in the right pelvic side wall, posterior to the cecum, with
multiple small yellowish nodules on the pelvic floor and peritoneal surface. Overall there was no gross evidence of disease. The pelvic washings and multiple biopsies were negative. The patient was alive and free
of disease 11 months after her second exploration.

Discussion
Many previous studies indicate that patients with primary
PSC have a worse prognosis than do those with ovarian cancer.
It is unclear whether this worse prognosis is due to the advanced
disease which is frequentiy found in this tumor or to unknown
inherent biological characteristics. We present a case of primary
PSC and extensive peritoneal involvement with absence of disease surgically documented after chemotherapy.
Malignant tumors involving the peritoneum are usually due
to metastatic ovarian carcinoma, tn rare cases, no primary tumor
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can be found and a primary tumor of the peritoneum must be
considered. Of course other primary tumors must be ruled out.
As in ovarian serous tumors, benign, borderiine, and malignant
variants of papillary serous tumors have been reported (3). Benign or borderline peritoneal tumors must be differentiated morphologically from mesotheliomas (4). PSC is frequentiy described microscopically as showing mitotic figures and many
psammoma bodies (5,6). Most PSC tumors have at teast a few
celts that show cytoplasmic or surface mucin and stain positively for keratin and epithelial membrane antigen. Other markers such as Leu-Ml, B72.3, vimentin, HPLAP, and CEA are
found in a small percentage of cells (6,7). In fact, on the basis of
light microscopy and histochemical and immunohistochemical
characteristics, PSC cannot be differentiated from ovarian carcinoma. This lack of cytochemical discrimination is explained by
the common histogenesis of these neoplasms. Both the peritoneal mesothelium and the surface epithelium of the ovary develop from the embryonic coelomic epithelium. The commonly
accepted theory for the origin of peritoneal papillary carcinoma
is that it arises directly from the mesodermal lining of the abdominal cavity in response to an unknown oncogenic stimulus
(4,8). On the other hand, some believe that PSC arises from embryonic rest cells (5). In any event, the coelomic origin of these
tumors explains their resemblance in many respects to ovarian
cancer. The fact that PSC has occurred in patients after bilateral
salpingo-oophorectomy supports the concept of its peritoneal
origin (9).
PSC affects only women, whose median age is about 60 years
(4,10), Abdominal pain and distension are the most common
presenting symptoms (6,9) while a palpable mass is uncommon
(4) . Radiological studies including CT are usually not helpful in
diagnosis (6). In most cases the entire mesothelial surface is involved and the tumor is rarely predominant in or limited to the
pelvis. Generally the ovaries are invotved only superficially and
are of normal size. When the tumor invades the ovaries, one encounters superficial involvement as well (6). PSC frequentiy involves the submesothelium, but deep invasion into the abdominal or pelvic organs or either local or distant metastases are rare
(5) . Spread of the disease outside the abdominal cavity producing malignant pleural effusion has been described (9). Ascitic
fluid, when present, usually contains malignant cells.
The median survival time of patients with PSC is between 11
and 24 months, simitar to those of the same age group who have
ovarian cancer (2,9). Some have found that peritoneal tumor has
a worse prognosis than ovarian cancer (11,12). White most series report only a few long-term survivors. Ransom et al (13) described three patients who lived over six years. Chen and Flam
(3) atso reported long-term survival after cisplatin-based chemotherapy. These patients had undergone optimal debulking
surgery followed by cytoxan-cisplatin chemotherapy.
There is no consensus as to the best therapy for peritoneal carcinoma, but most authors prefer to treat it in the same manner as
ovarian cancer (2,4,9). Complete clinical response to postoperative chemotherapy has been reported in 20% to 25% of patients
(2,4,6), but not all respond so favorably (13). Patients treated
with combination chemotherapy do better than those treated
with single agents and cisplatin-based regimens seem to be
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Figure—Papillary serous carcinoma ofthe peritoneum (hematoxylin-eosin stain, X50).

more effective (4). Contrary to other authors, Fromm et at (4) in
their large series of 74 patients found that neither chronologic
age nor the presence of residual disease after cytoreduction determined prognosis. This finding is in contrast with that found in
ovarian cancer. Fromm et al concluded that the absence of mitoses represented a favorable prognostic factor. Lele et al (2) described one patient with complete response to cisplatin, bleomycin, and cytosine arabinoside administered intraperitoneally.
Most studies conceming PSC of the peritoneum are retrospective and there is no staging system. Few reports allow conclusions about therapy, most focus on the pathology, and all are retrospective in nature. Only prospective studies conducted in
multiinstitutional clinical trials can provide reliable data about
the natural history of this disease. The vatue of intraperitoneal
chemotherapy must be carefully investigated. Our case suggests
that chemotherapy may be successful in treating unresectable
primary PSC of the peritoneum.

Acknowledgment
We thank Dr. Amnuay Singhakowinta for his assistance and
Philip Dvoretsky for his critical review of the pathology.

References
1. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary
cystadenocarcinoma of the ovary: Case report. Am J Obstet Gynecol 1959;77:
197-200.
2. Lele SB, Piver MS, Matharu J, Tsukada Y. Peritoneal papillary carcinoma.
Gynecol Oncol 1988;31:315-20.
3. Chen KT. Flam MS. Peritoneal papillary serous carcinoma with long-term
survival. Cancer 1986;58:1371-3.
4. Fromm G-L, Gershenson DM, Silva EG, Papillary serous carcinoma of the
peritoneum. Obstet Gynecol 1990;75:89-95.
5. Kannerstein M, Churg J, McCaughey WTE, Hill DP. Papillary tumors of
the peritoneum in women: Mesothelioma or papillary carcinoma. Am J Obstet
Gynecol 1977;127:306-14.
6. Tmong LD, Maccato ML, Awah H, Cagle PT, Schwartz MR, Kaplan AL.
Serous surface carcinoma of the peritoneum: A clinicopathologic study of 22
cases. Hum Pathol 1990;21:99-110.
7. Raju U, Fine G, Greenawald KA, Ohorodnik JM. Primary papillary serous
neoplasia of the peritoneum: A clinicopathologic and ultra.stmctural study of

Cure of Unresected Peritoneal Cancer—Saleh et al 137

eight cases. Hum Pathol 1989;20:426-36.
8. Parmley TH, Woodruff JD, The ovarian mesothelioma. Am J Obstet Gynecol 1974;120:234-41.
9. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous
papillary carcinoma: A clinicopathologic study of 31 ca.ses. Cancer 1989:64:
110-5.
10. Clement PB. Endometriosis, lesion of the secondary mullerian system and
pelvic mesothelial proliferation. In: KurmanRJ.ed. Blaustein's pathology ofthe
female genital tract. New York: Springer-Verlag, 1987:438-70.

138 Henry Ford Hosp Med J—Vol 40, Nos I & 2, 1992

11. Gooneratne S. Sassone M, Blaustein A, Talerman A. Serous surface papillary carcinoma of the ovary: A clinicopathologic study of 16 cases. Int J Gynecol
Pathol 1982;1:258-69.
12. Mills SE, Andersen WA, Fechner RE, Au.stin MB. Serous surface papillary carcinoma: A clinicopathologic study of 10 cases and comparison with stage
III-IV ovarian serous carcinoma. Am J Surg Pathol 1988; 12:827-34.
13. Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH, Papillary .serous carcinoma of the peritoneum: A review of 33 cases treated with
Platin-based chemotherapy. Cancer 1990:66:1091-4,

Cure of Unresected Peritoneal Cancer—Saleh et al

